Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

To investigate the efficacy, safety, and pharmacokinetics when R435 and paclitaxel are administered concomitantly to patients with metastatic breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chugai Pharmaceutical
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Paclitaxel

Criteria

• At least 20 years old and obtained a written informed consent

• Advanced breast cancer (StageⅣ) or Inoperable metastatic breast cancer

• HER2 negative

• At least one measurable lesion based on RECIST criteria

• No previous chemotherapy for metastatic breast cancer